**Date:** May 10, 2023 **Your Name:** Ricardo Avila

Manuscript Title: Calibration Phantom-based Prediction of CT Lung Nodule Volume Measurement

Performance

Manuscript number (if known): QIMS-22-320-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Accumetra, LLC	Ricardo Avila is the CEO of Accumetra, LLC where this work was performed.
2	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	None  None	36 months
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	Yes	Accumetra holds and has submitted patents on the topic of CT image quality.
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	Own Stock	I own Accumetra stock.
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Yes	
	financial interests	Paraxial, LLC	Ricardo Avila is the owner and CEO of Paraxial.
		Kitware, Inc.	Lisa Avila is the CEO of Kitware.

Ricardo Avila is the CEO and owns stock in Accumetra. Accumetra also holds and submits patents in the area of CT image quality. He is also the owner of Paraxial, LLC which develops imaging software and other technologies. Ricardo Avila's wife (Lisa Avila) is the CEO of Kitware which also develops imaging software and other technologies.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:May 12 <sup>th</sup> , 2023
Your Name:Karthik Krishnan
Manuscript Title:Calibration Phantom=based Prediction of CT Lung Nodule Volume Measurement Performance_
Manuscript number (if known):QIMS-22-32R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co		

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May 10, 2023

Your Name: Nancy Obuchowski

Manuscript Title: Calibration Phantom-based Prediction of CT Lung Nodule Volume Measurement Performance

Manuscript number (if known): QIMS-22-320-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	QIBA	Dr Obuchowski provides statistical consultation to QIBA through a contract between her institution and RSNA. (No \$ to Obuchowski)
3	Royalties or licenses	X_None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	ne e
lectures, presentations, speakers bureaus, manuscript writing or	ne e
speakers bureaus, manuscript writing or	
educational events	
6 Payment for expertX_Nor testimony	ne
7 Support for attendingXNor meetings and/or travel	ie
8 Patents planned, issued or <u>X Nor</u> pending	ne e
9 Participation on a Data X_Nor Safety Monitoring Board or	ie e
Advisory Board	
10 Leadership or fiduciary roleXNor in other board, society,	ne e
committee or advocacy group, paid or unpaid	
11 Stock or stock optionsX_Nor	ie e
12 Receipt of equipment,X_Nor	ne l
materials, drugs, medical	
writing, gifts or other services	
13 Other financial or non- X_Nor	ne e
financial interests	

Dr Obuchowski provides statistical consultation to QIBA through a contract between her institution and RSNA. (No \$
to Obuchowski)

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:May 12, 2023
Your Name:Artit Jirapatnakul
Manuscript Title: Calibration Phantom-based Prediction of CT Lung Nodule Volume Measurement
Performance
Manuscript number (if known):QIMS-22-320

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Prevent Cancer Foundation	Payment made to institution
3	Royalties or licenses	X_None	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	<u> </u>	V N	
/	Support for attending meetings and/or travel	XNone	
	G ,		
8	Patents planned, issued or	X None	
Ü	pending		
	h a manual		
9	Participation on a Data	X None	
9	Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	

I received a 2-year \$100k grant from the Prevent Cancer Foundation for a project to model factors influencing nodule measurement uncertainty. The grant was paid to my institution and ended in Jan 2021. This is not directly related to this manuscript other than the overarching theme of trying to make better measurements.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:4/30/2023				
You	r Name:David Yan	kelevitz			
	Manuscript Title: Calibration Phantom-based Prediction of CT Lung Nodule Volume Measurement Performance Manuscript number (if known):				
rela part to ti rela	ted to the content of your manager in the series whose interests may be the ransparency and does not not too ship/activity/interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do			
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>		
to tl med In it	he epidemiology of hyperter lication, even if that medica	nsion, you should declare a tion is not mentioned in th port for the work reported	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive me manuscript.  in this manuscript without time limit. For all other items,		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initia	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_xNone			
		Time frame: past	36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone			
3	Royalties or licenses	None	Advisory board and owns equity in HeartLung Dr. Yankelevitz is a named inventor on a number of patents and patent applications related to the evaluation of chest diseases including measurements of chest nodules. Dr. Yankelevitz has received		

 $financial\ compensation\ for\ the\ licensing\ of\ these$ 

patents.

4	Consulting fees	None	Consulted for Genentech, AstraZeneca and Pfizer (unpaid)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_xNone	
6	Payment for expert testimony	_xNone	
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or pending	None	Dr. Yankelevitz is a named inventor on a number of patents and patent applications related to the evaluation of chest diseases including measurements of chest nodules. Dr. Yankelevitz has received financial compensation for the licensing of these patents.
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	Advisory board and owns equity in HeartLung  Medical advisory board of Median Technology, Carestream
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_xNone	
11	Stock or stock options	None	Consultant and co-owner of Accumetra Advisory board and owns equity in HeartLung
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_xNone	
13	Other financial or non- financial interests	_xNone	

Dr. Yankelevitz is a named inventor on a number of patents and patent applications related to the evaluation of chest diseases including measurements of chest nodules. Dr. Yankelevitz has received financial compensation for the licensing of these patents. In addition, he is a consultant and co-owner of Accumetra, a private company developing tools to improve the quality of CT imaging. He is on the advisory board and owns equity in HeartLung, a company that develops software related to CT scans of the chest. He is on the medical advisory board of Median Technology that is developing technology related to analyzing pulmonary nodules and is on the medical advisory board of Carestream, a company that develops radiography equipment and has consulted for Genentech, AstraZeneca and Pfizer.

## Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.